-+ 0.00%
-+ 0.00%
-+ 0.00%
CSPC Innovation announced that the holding subsidiary Jushi Biotech previously signed an “Exclusive License Agreement” with Corbus in February 2023, granting it an exclusive license to develop and commercialize CRB-701 within the cooperative region. On November 18, 2026, Jushi Biotech received a milestone payment of 15 million US dollars from Corbus. The actual payment amount must be deducted from bank charges; up to now, it had received a total of 17.5 million US dollars in initial payments and milestone payments under this agreement. This payment is expected to have a positive impact on the company's performance and financial situation. The exact amount is subject to audit data. Subsequent development milestone payments, sales milestone payments, and royalties are triggered by agreed clinical research and development, regulatory approval, sales completion status, etc., and there is still uncertainty about the final amount.
Share
Listen to the news
CSPC Innovation announced that the holding subsidiary Jushi Biotech previously signed an “Exclusive License Agreement” with Corbus in February 2023, granting it an exclusive license to develop and commercialize CRB-701 within the cooperative region. On November 18, 2026, Jushi Biotech received a milestone payment of 15 million US dollars from Corbus. The actual payment amount must be deducted from bank charges; up to now, it had received a total of 17.5 million US dollars in initial payments and milestone payments under this agreement. This payment is expected to have a positive impact on the company's performance and financial situation. The exact amount is subject to audit data. Subsequent development milestone payments, sales milestone payments, and royalties are triggered by agreed clinical research and development, regulatory approval, sales completion status, etc., and there is still uncertainty about the final amount.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending